-+ 0.00%
-+ 0.00%
-+ 0.00%

ALPHA TAU SUBMITS FIRST PRE-MARKET APPROVAL MODULE TO THE FDA FOR ALPHA DART® FOR THE TREATMENT OF RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

路透·01/05/2026 14:00:01

登錄查看新聞詳情